Under the influence of interleukin-1α (IL-1α) and interleukin-1β (IL-1β), MSCs produce prostaglandin E2 (PGE2), resulting in increased cyclooxygenase-2 (COX-2) expression resulting in cancer progression and its drug resistance [27,28]. The gene discussed is PTGS2; the disease is cancer.